Text Size

Monitoring Pulmonary Artery Pressure by Implantable Device Responding to Ultrasonic Signal (PAPIRUS III)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by:
Boston Scientific Corporation
ClinicalTrials.gov Identifier:
NCT00893828
First received: May 5, 2009
Last updated: May 3, 2012
Last verified: May 2012
History of Changes
  Purpose

The PAPIRUS III study will continue to follow patients initially enrolled in PAPIRUS II. Pressure readings from the investigational device will continue to be collected and will be correlated to physiological changes during activities of daily living and protocol defined tests.


Condition
Heart Failure

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Monitoring Pulmonary Artery Pressure by Implanted Device Responding to Ultrasonic Signal

Resource links provided by NLM:

MedlinePlus related topics: Heart Failure
U.S. FDA Resources

Further study details as provided by Boston Scientific Corporation:

Primary Outcome Measures:
  • Continue detailed data collection of pressure readings from patients implanted with a RemonCHF device. [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]

Biospecimen Retention:   None Retained

Whole Blood


Estimated Enrollment: 20
Study Start Date: March 2009
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients previously implanted with a RemonCHF device

Criteria

Inclusion Criteria:

  • Patient has been enrolled in the PAPIRUS II Study and has a RemonCHF pressure sensor implanted
  • Patient is willing and able to provide informed consent, participate in the Safety Follow-up Program and/or in the required tests associated with the clinical investigation (Core Study Program) at an approved clinical investigational center and at the intervals defined by the Clinical Investigational Plan.

Exclusion Criteria:

  • Patient enrolled in PAPIRUS II but not implanted with a RemonCHF Pressure Sensor
  • Patients who are currently enrolled in another investigational study or registry that would directly interfere with the current study (with the exception of the PAPIRUS II Study). Each instance would be brought to the sponsor to determine eligibility.
  • Age < 18 years
  • Women of childbearing potential who are, or might be, pregnant at the time of the study
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00893828

Locations
Germany
University of Cologne
Cologne, Germany
Sponsors and Collaborators
Boston Scientific Corporation
Investigators
Principal Investigator: Uta C Hoppe, Prof. Dr. University of Cologne
  More Information

No publications provided

Responsible Party: Bernd Schubert, MD, Boston Scientific Corporation
ClinicalTrials.gov Identifier: NCT00893828     History of Changes
Other Study ID Numbers: Rev. B, 29-Sep-08
Study First Received: May 5, 2009
Last Updated: May 3, 2012
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Additional relevant MeSH terms:
Heart Failure
Heart Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on May 23, 2013